Haleon updates share count and voting rights

In a recent regulatory filing, Haleon plc (LSE/NYSE: HLN), a prominent player in the consumer health sector with a market capitalization of $41.7 billion, disclosed its updated total number of shares and voting rights. As of January 31, 2025, the company reported a total issued share count of 9,083,725,919 ordinary shares, each with a nominal value of £0.01. Out of these, 29,580,205 shares are held in treasury.

Consequently, the total number of ordinary shares carrying voting rights stands at 9,054,145,714. This figure is pivotal for shareholders and others with notification obligations, as it serves as the denominator for calculating changes in shareholding interests that need to be disclosed under the Financial Conduct Authority’s (FCA) Disclosure Guidance and Transparency Rules. According to InvestingPro, Haleon demonstrates strong financial health with a GOOD overall score and maintains a healthy gross profit margin of 62.2%.

Haleon, known for its portfolio of trusted brands like Advil, Sensodyne, and Centrum, emphasizes its commitment to enhancing everyday health through its products, which cover a broad spectrum including Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements. The company currently offers a dividend yield of 1.11% and trades at a P/E ratio of 28.4.

The company, which was previously known as DRVW 2022 Ltd until its name change on December 17, 2021, is headquartered in Weybridge, Surrey, with its shares traded on both the London and New York Stock Exchanges. The stock currently trades near its 52-week high, showing strong momentum despite market volatility. Discover more insights and detailed analysis with InvestingPro’s comprehensive research report, available along with many more features for subscribers.

The information provided in this article is based on a press release statement from Haleon plc.

In other recent news, Haleon plc reported significant earnings and revenue results, including a £230 million off-market share repurchase from Pfizer Inc. (NYSE:PFE) The company increased its stake in the Chinese joint venture, Tianjin TSKF Pharmaceutical (TADAWUL:2070) Co. Ltd, to 88%, and finalized the divestment of its nicotine replacement therapy business to Dr. Reddy’s Laboratories SA in a deal worth up to £500 million. Haleon’s Chief Financial Officer, Dawn Allen, vested an award of Haleon Ordinary Shares and sold a portion to cover tax obligations, retaining a significant number of shares.

Key changes to Haleon’s board were also announced, with David Denton resigning as a Non-Executive Director and Bláthnaid Bergin stepping in as an independent Non-Executive Director. In terms of analyst ratings, Bernstein downgraded Haleon’s stock from ’Outperform’ to ’Market Perform’, Morgan Stanley (NYSE:MS) maintained an Overweight rating, and Goldman Sachs downgraded Haleon’s stock from "Buy" to "Neutral." Berenberg initiated coverage with a "Buy" rating. Two of Haleon’s key executives, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers (NYSE:ROG), acquired shares as part of the company’s Share Reward Plan.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.